+91 789 2456 581 | info@nckpharma.com

Please sign in first

Username

Password

Lost Your Password?

Not a member?

Please simply create an account before buying/booking any courses.

Create an account for free!

Home
- About Us
- Contact
NCK services
Course List
Admission
Corporate Training
Knowledge Base

Home
- About Us
- Contact
NCK services
Course List
Admission
Corporate Training
Knowledge Base

Pharma News

Keep updating your pharma knowledge

24 Sep 2017

What are the major differences between – Breakthrough Therapy Designation Vs. Fast Track Designation Vs. Priority Review Designation Vs. Accelerated Approval

/

Posted Byadmin

/

Comments0

/

TagsAccelerated Approval, Breakthrough Therapy designation, Fast Track designation, FDA grants Priority Review for potential new indication for Brilinta, priority review, Priority Review Designation, usfda accelerated approval

Here is a quick comparison of the USFDA drug development expedited programs. This may help you to distinguishing all of them effectively.

Related Articles

Insighht on USFDA approval of Trikafta
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
Turalio: USFDA approval of first therapy for rare joint tumor
Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab

European approval for Roche’s tocilizumab for the treatment of giant cell arteritis (GCA)

USFDA approval of Verzenio to treat certain advanced/metastatic breast cancers

About Post Author

admin

Leave a Reply Cancel Reply

Search With Term

Recent Industry Update

How biosimilar priced in US market?
Pfizer launched Zirabev, Ruxience, Trazimera biosimilar in US
Merck’s Dificid received USFDA approval for Infections in Children
EyePoint Pharmaceuticals and Ocumension Therapeutics’s Exclusive License Agreement to Develop and Commercialize DEXYCU
Helsinn out-licenses Akynzeo and Onicit in Russia to Berlin-Chemie
Insight on 2019 USFDA New Drug Approval
Insight on J&J’s TB mass awareness campaign in India
CUTX-101 of Fortress Biotech gets US FDA rare pediatric disease designation to treat Menkes disease
What is Edible security tag?
Acquisition in Pharma: Why Astellas to acquire Xyphos Biosciences?
US FDA issued CRL to ViiV Healthcare for use of cabotegravir and rilpivirine long-acting regimen for treatment of HIV
US FDA issues Complete Response Lette to Takeda’s Entyvio for maintenance therapy in adults with ulcerative colitis
What is ISO 15197:2013 certification?
Copromotion deal for Japan – Gilead and Eisai in RA therapy filgotinib
Insight on USFDA approval of Allergan’s Ubrelvy
Insight on Alteogen’s non-exclusive licensing deal for ALT-B4 to a top 10 global pharma
Pharma Strategic Deal: Astellas Pharma to acquire Audentes Therapeutics for about $3 billion
Pharma Business Development – Competency Test. Check your competency
Case study: Novartis to acquire The Medicines Company for $9.7 billion, get hold of inclisiran, a cholesterol drug
What is USFDA Purple Book? What it’s significance?
USFDA approved Pfizer’s Abrilada, a biosimilar of Humira
Pfizer’s Upjohn and Mylan merged business entity will be namea as Viatris
Bayer and Dewpoint Therapeutics co-development deal for cardiovascular and gynecological diseases
Sandoz to Acquire Japanese Biz of AGI
Selumetinib NDA Submission for Neurofibromatosis Type 1 (NF1) granted Priority Review
Insignt on Roche’s Up-to-$1.4Billion Promedior Acquisition
Case Study: 505(b)(2) filing pathway – USFDA approval of Vumerity
What is the significance of Clinical Hold of investigational molecules?
US FDA places partial hold on Novartis’ AVXS-101 intrathecal study
Zentiva to acquire CEE pharma business of Alvogen

Monthly Archieves

Certification Courses

View our online Certification Courses.

Related Articles

Insighht on USFDA approval of Trikafta
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
Turalio: USFDA approval of first therapy for rare joint tumor
Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab

Corporate Training

View list of courses, simulation, e-books, libararies for Pharma Corporate, Government and Regulatory Bodies.

Related Articles

Insighht on USFDA approval of Trikafta
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
Turalio: USFDA approval of first therapy for rare joint tumor
Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
US FDA grants priority review status to Novartis’ sickle cell molecule crizanlizumab

Subscribe to NCK Newsline

Enter your email address:

Delivered by FeedBurner

Popular 1 Year Courses

KPE – C- 024 KPE’s Executive Program in Pharmaceutical Global Business
KPE-C-001 KPE’s Advance Diploma in Pharmaceutical Product Management
KPE-C-003 KPE’s Advance Diploma in Drug Regulatory Affairs
KPE-C-004 KPE’s Advance Diploma in Pharma Marketing
KPE – C- 009 KPE’s Advance Diploma in Pharmacovigilance
KPE-C-005 KPE’s Advance Diploma in Pharmaceutical Production management
KPE-C-08 KPE’s Advance Diploma in Pharmaceutical Strategic Business Management

Javascript is disabled

Javascript is disabled on your browser. Please enable it in order to use this form.

Loading

Query

First Name

Last Name

Email Address

Your Query *

Write Here

9 plus 3 equals?*

Prove you are a human

Write here

Your form has been submitted

Thank you %NAME% for the submitting your query/feedback.

Server Side Error

We faced problems while connecting to the server or receiving data from the server. Please wait for a few seconds and try again.

If the problem persists, then check your internet connectivity. If all other sites open fine, then please contact the administrator of this website with the following information.

TextStatus: undefined
HTTP Error: undefined

Processing your request

Error

Some error has occured.

Disclaimer & Privacy Policy | Terms of Use

Copyright © 2014 - 2015 All Right Reserved - NCK Pharma Solution Private Limited

This website uses cookies to improve your learning experience. Ok Privacy Policy

Privacy & Cookies Policy

Necessary Always Enabled

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests

etc.